XRP0038 (NV1FGF)

DRUG5 trials

Sponsors

Sanofi

Conditions

Peripheral Arterial DiseasePeripheral Arterial Occlusive DiseaseSevere Peripheral Artery Occlusive Disease

Phase 1

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

CompletedNCT01157156

SanofiPeripheral Arterial Occlusive Disease

Start: 1999-06-30End: 2001-09-30Updated: 2010-07-05

Gene Expression and Tolerability Study of NV1FGF in Patients With Peripheral Artery Occlusive Disease Planned to Undergo Major Amputation

CompletedNCT01157143

SanofiPeripheral Arterial Occlusive Disease

Start: 2002-01-31End: 2003-10-31Updated: 2010-07-05

Phase 2

Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

CompletedNCT00368797

SanofiPeripheral Arterial Disease

Start: 2002-03-31End: 2005-04-30Updated: 2008-11-18

Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.

CompletedNCT00798005

SanofiSevere Peripheral Artery Occlusive Disease

Start: 2002-06-30End: 2005-07-31Updated: 2017-06-08

Dose-finding, Safety and Efficacy Study of NV1FGF in Patients With Intermittent Claudication

CompletedNCT01157871

SanofiPeripheral Arterial Occlusive Disease

Start: 2004-06-30End: 2005-08-31Updated: 2010-07-07